Albert David Ltd (ALBERTDAVD) AI Stock Analysis

• Market Cap: ₹3.95B
• Dividend Yield: 0.66%
• Average Volume (3M): 210.00
• Price to Earnings (P/E): ―
• Beta (1Y): 1.20
• Revenue Growth: -13.51%
• EPS Growth: -122.00%
• Country: IN
• Employees: 1,497
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -5.79
• Shares Outstanding: 5,707,162
• 10 Day Avg. Volume: 184
• 30 Day Avg. Volume: 210
• PEG Ratio: -0.36
• Price to Book (P/B): 1.21
• Price to Sales (P/S): 1.37
• P/FCF Ratio: -10.94
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 51 Neutral
• Price Target: ₹695.00 ▼(-11.85% Downside)

Albert David Ltd's overall stock score is primarily impacted by its strong balance sheet, which is overshadowed by declining financial performance and bearish technical indicators. The negative P/E ratio and low dividend yield further weigh on the valuation.

Positive Factors

Strong balance sheet

Low leverage and robust equity provide durable financial flexibility, lowering insolvency risk and supporting capital allocation. This strength allows the company to withstand cyclical downturns, fund selective investments or tenders, and preserve credit capacity over the next several quarters.

Healthy gross margins

Sustained strong gross margins reflect structural cost competitiveness or pricing power in formulations. This margin buffer helps absorb input cost volatility and supports reinvestment into manufacturing, compliance, or marketing, underpinning medium-term profitability resilience.

Domestic and export channels

Exposure to both domestic healthcare channels and export markets diversifies revenue sources and reduces dependence on a single geography. That distribution breadth supports steady demand, mitigates region-specific regulatory or pricing risks, and helps stabilize revenue over time.

Negative Factors

Declining revenue

Material year-over-year revenue contraction signals weakening demand or market share loss. Persistent top-line decline compresses operating leverage, limits reinvestment capacity, and can degrade supplier or customer relationships, posing a multi-quarter threat to growth prospects.

Negative operating and free cash flow

Negative operating and free cash flow undermines liquidity and internal funding for capex, working capital, and compliance. Even with low debt, sustained cash deficits may force external financing, dilute equity, or constrain strategic initiatives, weakening long-term operational flexibility.

Profitability deterioration / EPS collapse

Severe EPS decline and falling net margins point to structural earnings pressure from pricing, mix shifts, or rising costs. This erosion reduces retained earnings, limits capacity to invest in growth, and raises concerns about sustainable returns to shareholders over the coming quarters.

Albert David Ltd Business Overview & Revenue Model

Company Description

Albert David Limited manufactures and trades in pharmaceutical formulations, infusion solutions, herbal dosage forms, bulk drugs, and disposable syringes and needles in India. It offers formulations for parenterals, oral/enteral, topical agents, and vision care products. The company also exports its products to Latin American, Southeast Asian, and other African countries. The company was incorporated in 1938 and is headquartered in Kolkata, India.

How the Company Makes Money

Albert David Ltd generates revenue through multiple streams, primarily by selling its medical devices and healthcare products to hospitals, clinics, and healthcare distributors. The company engages in direct sales and also leverages partnerships with key healthcare organizations and distributors to expand its market reach. Additionally, Albert David may earn revenue through service contracts, maintenance agreements, and training programs associated with their products. The company's strategic collaborations with research institutions and healthcare providers also contribute to its earnings by facilitating product development and enhancing its market competitiveness.

Albert David Ltd Financial Statement Overview

Summary

Albert David Ltd shows a strong balance sheet with low leverage and solid equity, but faces challenges with declining revenue, profitability, and negative cash flows. These issues need addressing for sustainable growth.

Income Statement

Albert David Ltd has shown a mixed performance in terms of revenue and profitability. The gross profit margin is strong, indicating effective cost management, but the net profit margin has declined significantly in the latest year, reflecting a decrease in profitability. Revenue has shown fluctuations, with a notable decline in the most recent year, which is a concern for growth prospects.

Balance Sheet

The company's balance sheet reflects solid equity and a low level of debt, which is a positive indicator of financial stability. The equity ratio is robust, and the company has maintained a strong return on equity, although it has decreased in the latest year. The low debt-to-equity ratio limits financial risk.

Cash Flow

Cash flow from operations has turned negative in the latest year, which is a significant drawback. Free cash flow also fell into negative territory, indicating potential liquidity issues. In previous years, cash flow metrics were healthier, but the recent downturn in free cash flow growth rate raises concerns about the company's ability to generate cash.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	3.27B	3.46B	3.60B	3.42B	3.12B	2.46B
Gross Profit	2.16B	2.29B	2.32B	2.18B	1.95B	1.58B
EBITDA	-95.32M	30.26M	1.05B	598.68M	567.76M	364.59M
Net Income	62.94M	172.01M	754.20M	361.75M	352.58M	221.43M
Balance Sheet
Total Assets	0.00	5.11B	4.98B	4.23B	4.03B	3.41B
Cash, Cash Equivalents and Short-Term Investments	2.44B	2.44B	2.85B	2.03B	1.75B	1.49B
Total Debt	0.00	123.17M	33.24M	53.18M	56.62M	16.19M
Total Liabilities	-3.92B	1.19B	1.15B	1.12B	1.23B	970.20M
Stockholders Equity	3.92B	3.92B	3.83B	3.12B	2.79B	2.44B
Cash Flow
Free Cash Flow	0.00	-432.92M	346.28M	52.78M	292.83M	349.79M
Operating Cash Flow	0.00	-284.36M	455.02M	105.15M	403.65M	366.11M
Investing Cash Flow	0.00	233.01M	-332.48M	-49.95M	-396.97M	-366.84M
Financing Cash Flow	0.00	1.10M	-82.70M	-63.62M	-12.59M	-17.05M

Albert David Ltd Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 788.40
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ALBERTDAVD, the sentiment is Negative. The current price of 788.4 is above the 20-day moving average (MA) of 712.02, above the 50-day MA of 744.44, and below the 200-day MA of 810.99, indicating a bearish trend. The MACD of -18.42 indicates Negative momentum. The RSI at 40.14 is Neutral, neither overbought nor oversold. The STOCH value of 56.34 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:ALBERTDAVD.

Albert David Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ZIMLAB	63 Neutral	₹3.48B	52.76	―	―	-5.82%	-59.22%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ALBERTDAVD	51 Neutral	₹3.95B	-26.19	―	0.66%	-13.51%	-122.00%
LYKALABS	51 Neutral	₹2.55B	-390.11	―	―	4.04%	-35.02%
NECLIFE	46 Neutral	₹3.01B	-0.85	―	―	-30.27%	-3470.06%
VIKASLIFE	46 Neutral	₹3.16B	-28.05	―	―	9.42%	-12220.00%
BROOKS	45 Neutral	₹1.82B	13.28	―	―	18.67%	―

Albert David Ltd Corporate Events

Albert David to Close Trading Window Ahead of Q3 FY2025-26 Results

Albert David Limited has announced that its trading window for dealing in the company’s shares will be closed from 1 January 2026 in line with SEBI’s Prohibition of Insider Trading Regulations and the company’s internal code of conduct on insider trading. During this period, designated persons, insiders and their immediate relatives are barred from trading in the company’s securities, with additional controls including PAN-level freezing of designated persons’ accounts via CDSL, until 48 hours after the release of its unaudited financial results for the third quarter and nine months ended 31 December 2025; the board meeting date to consider these results will be announced separately.